申请人:TERUMO KABUSHIKI KAISHA
trading as TERUMO CORPORATION
公开号:EP0194686A1
公开(公告)日:1986-09-17
Novel pyrazine derivatives are disclosed. The compounds possess a potent platelet aggregation-inhibiting activity and are effective for preventing diseases caused by aggregation of the platelet, for example, myocardial infarction and cerebral thrombosis. Representative examples of the pyrazine derivatives include 2,3-bis (p-chlorophenyl)-5-methylpyrazine, 2,3-bis(p-methoxyphenyl)-5-methylpyrazine, 2,3-diphenyl-5-benzylpyrazine, 2,3-diphenyl-5-(p-methoxybenzyl) pyrazine, 2,3-bis (p-methoxyphenyl)-5-isopropylpyrazine, 2,3-bis)p-methoxyphenyl)-5-(2-thienylmethyl) pyrazine and 2,3-bis-(p-methoxyphenyl)-5,6-dimethylpyrazine.
The pyrazine derivatives can be generally prepared by heating a benzil derivative and a 1, 2-diaminoethane derivative to produce a dihydropyrazine derivative and heating the resulting compound with sulfur at 100 - 180°C.
本研究公开了新型吡嗪衍生物。这些化合物具有强效的血小板聚集抑制活性,可有效预防由血小板聚集引起的疾病,如心肌梗塞和脑血栓。吡嗪衍生物的代表性实例包括 2,3-双(对氯苯基)-5-甲基吡嗪、2,3-双(对甲氧基苯基)-5-甲基吡嗪、2,3-二苯基-5-苄基吡嗪、2、2,3-双(对甲氧基苯基)-5-异丙基吡嗪、2,3-双(对甲氧基苯基)-5-(2-噻吩基甲基)吡嗪和 2,3-双(对甲氧基苯基)-5,6-二甲基吡嗪。
吡嗪衍生物的制备方法一般是加热苯偶姻衍生物和 1,2-二氨基乙烷衍生物,生成二氢吡嗪衍生物,然后在 100-180°C 下用硫加热生成的化合物。